Myalepta (Metreleptin)

Metreleptin is a synthetic version of the hormone leptin. It binds to leptin receptors in the brain and peripheral tissues, re‑activating signaling pathways that control hunger, energy expenditure, and glucose‑lipid balance, thereby compensating for the deficiency that underlies lipodystrophy.

The dosage of Myalepta is individualized. A qualified prescriber determines the appropriate amount and administration schedule based on the patient’s clinical condition, body weight, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for metreleptin in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician in consultation with the patient.

To request Myalepta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Myalepta is a leptin replacement therapy, directly addressing the underlying hormone deficiency, whereas other options such as dietary management, insulin, or lipid‑lowering drugs treat symptoms without correcting leptin levels. This mechanism can lead to broader metabolic improvements, but suitability depends on individual patient factors.

Myalepta must be stored in a refrigerated environment between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain product stability.

Myalepta is given as a subcutaneous injection. The prescriber will instruct the patient or caregiver on the injection site, technique, and frequency, which is typically once daily or as otherwise directed based on clinical response.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, the development of anti‑leptin antibodies that may reduce efficacy, and rare autoimmune events. Patients should be monitored closely for any signs of allergic reaction or unexpected immune‑mediated symptoms.

Myalepta is contraindicated in individuals with known hypersensitivity to metreleptin or any excipients in the formulation, and it should be avoided in patients receiving live vaccines or those with uncontrolled active infections unless the prescriber determines the benefits outweigh the risks.